Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in adv...

Full description

Bibliographic Details
Main Authors:	Deborah Cosentini, Salvatore Grisanti, Alberto Dalla Volta, Marta Laganà, Chiara Fiorentini, Paola Perotti, Sandra Sigala, Alfredo Berruti
Format:	Article
Language:	English
Published:	Bioscientifica 2018-11-01
Series:	Endocrine Connections
Online Access:	https://ec.bioscientifica.com/view/journals/ec/7/12/EC-18-0398.xml

Similar Items

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
by: Chiara Fiorentini, et al.
Published: (2019-01-01)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
by: Salvatore Grisanti, et al.
Published: (2021-02-01)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
by: Deborah Cosentini, et al.
Published: (2021-04-01)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
by: Marta Laganà, et al.
Published: (2020-04-01)

Adrenocortical Carcinoma
by: Alfredo Berruti, et al.
Published: (2021-03-01)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
by: Roberta Ambrosini, et al.
Published: (2020-05-01)

Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
by: Andrea Abate, et al.
Published: (2020-04-01)

Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study
by: Guido Alberto Massimo Tiberio, et al.
Published: (2020-04-01)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
by: Elisa Rossini, et al.
Published: (2021-06-01)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
by: Elisa Rossini, et al.
Published: (2021-04-01)

The Immunotherapy Landscape in Adrenocortical Cancer
by: Guillaume J. Pegna, et al.
Published: (2021-05-01)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
by: Vittoria Basile, et al.
Published: (2020-09-01)

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
by: Abate, A., et al.
Published: (2022)

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma
by: Izabela Karwacka, et al.
Published: (2021-01-01)

Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report
by: Mélanie Claps, MD, et al.
Published: (2016-01-01)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
by: Antonina Germano, et al.
Published: (2018-01-01)

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
by: Natalia Georgantzoglou, et al.
Published: (2021-04-01)

Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance
by: Marta Araujo-Castro, et al.
Published: (2021-03-01)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
by: Xiaoxi Shi, et al.
Published: (2021-07-01)

Medical Approaches in Adrenocortical Carcinoma
by: Rosa Maria Paragliola, et al.
Published: (2020-11-01)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01)

Immunotherapy for Prostate Cancer: Where We Are Headed
by: Giuseppe Schepisi, et al.
Published: (2017-12-01)

Tata in Africa : where to next?
by: Cooper, David John Stuart
Published: (2013)

Radiography in Palaeopathology: Where Next?
by: Buckberry, Jo, et al.
Published: (2008)

Where Next for Genetics and Genomics?
by: Chris Tyler-Smith, et al.
Published: (2015-07-01)

Malaria vaccines: where next?
by: Anthony A Holder
Published: (2009-10-01)

Where is genomics going next?
by: Barbara Cheifet
Published: (2019-01-01)

Nutritional Psychiatry: Where to Next?
by: Felice N. Jacka
Published: (2017-03-01)

Where Next? Library Transformation
by: Stoffle, Carla J., et al.
Published: (2006)

Where Next for XidML
by: Cooke, Alan
Published: (2011)

Where next for microbiome research?
by: Matthew K Waldor, et al.
Published: (2015-01-01)

Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01)

A Case Report of Adrenocortical Carcinoma with Hypercortisolism and Heart Failure
by: Shiva Borzouei, et al.
Published: (2013-09-01)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
by: Soraya Puglisi, et al.
Published: (2019-11-01)

What Is Psychophysiology? Where to go next?
by: Kaneez Fatima Shad
Published: (2014-08-01)

E-learning in ophthalmology: Where next?
by: Kieran Walsh
Published: (2014-01-01)

Where next for macroecology: citizen macroecology?
by: Laura Jane Graham, et al.
Published: (2014-03-01)

The Government Information Road: Where Next?
by: Russell, Judy, et al.
Published: (2006)

Process Supply Chains Management - Where are we ? Where to go next ?
by: Ana Paula Barbosa-Povoa
Published: (2014-06-01)

Melanoma Immunotherapy: Next-Generation Biomarkers
by: Sabrina A. Hogan, et al.
Published: (2018-05-01)